Center of Neonatal Disease Screening, Quanzhou Maternity and Children's Hospital, 700 Fengze Street, Quanzhou, 362000, Fujian Province, China.
Hangzhou Biosan Clinical Laboratory, Hangzhou, 310007, Zhejiang Province, China.
Orphanet J Rare Dis. 2021 Aug 3;16(1):339. doi: 10.1186/s13023-021-01964-5.
Glutaric acidemia type 1 (GA1) is a treatable disorder affecting cerebral organic acid metabolism caused by a defective glutaryl-CoA dehydrogenase (GCDH) gene. GA1 diagnosis reports following newborn screening (NBS) are scarce in the Chinese population. This study aimed to assess the acylcarnitine profiles and genetic characteristics of patients with GA1 identified through NBS.
From January 2014 to September 2020, 517,484 newborns were screened by tandem mass spectrometry, 102 newborns with elevated glutarylcarnitine (C5DC) levels were called back. Thirteen patients were diagnosed with GA1, including 11 neonatal GA1 and two maternal GA1 patients. The incidence of GA1 in the Quanzhou region was estimated at 1 in 47,044 newborns. The initial NBS results showed that all but one of the patients had moderate to markedly increased C5DC levels. Notably, one neonatal patient with low free carnitine (C0) level suggest primary carnitine deficiency (PCD) but was ultimately diagnosed as GA1. Nine neonatal GA1 patients underwent urinary organic acid analyses: eight had elevated GA and 3HGA levels, and one was reported to be within the normal range. Ten distinct GCDH variants were identified. Eight were previously reported, and two were newly identified. In silico prediction tools and protein modeling analyses suggested that the newly identified variants were potentially pathogenic. The most common variant was c.1244-2 A>C, which had an allelic frequency of 54.55% (12/22), followed by c.1261G>A (p.Ala421Thr) at 9.09% (2/22).
Neonatal GA1 patients with increased C5DC levels can be identified through NBS. Maternal GA1 patients can also be detected using NBS due to the low C0 levels in their infants. Few neonatal GA1 patients may have atypical acylcarnitine profiles that are easy to miss during NBS; therefore, multigene panel testing should be performed in newborns with low C0 levels. This study indicates that the GCDH variant spectra were heterogeneous in this southern Chinese cohort.
戊二酸血症 1 型(GA1)是一种可治疗的疾病,影响大脑有机酸代谢,由缺陷型谷氨酰辅酶 A 脱氢酶(GCDH)基因引起。在中国人群中,新生儿筛查(NBS)后 GA1 的酰基肉碱谱分析和基因特征报告很少。本研究旨在评估通过 NBS 发现的 GA1 患者的酰基肉碱谱分析和基因特征。
2014 年 1 月至 2020 年 9 月,517484 名新生儿通过串联质谱法进行筛查,102 名肉碱水平升高的新生儿被召回。13 名患者被诊断为 GA1,包括 11 名新生儿 GA1 和 2 名母体 GA1 患者。泉州地区 GA1 的发病率估计为每 47044 名新生儿中就有 1 例。最初的 NBS 结果显示,除 1 例患者外,所有患者的 C5DC 水平均中度至显著升高。值得注意的是,1 例新生儿患者的游离肉碱(C0)水平较低,提示原发性肉碱缺乏症(PCD),但最终被诊断为 GA1。9 例新生儿 GA1 患者进行了尿液有机酸分析:8 例患者的 GA 和 3HGA 水平升高,1 例报告在正常范围内。共发现 10 种不同的 GCDH 变异。其中 8 种是先前报道过的,2 种是新发现的。基于生物信息学预测工具和蛋白质建模分析,新发现的变异可能具有致病性。最常见的变异是 c.1244-2A>C,等位基因频率为 54.55%(12/22),其次是 c.1261G>A(p.Ala421Thr),占 9.09%(2/22)。
通过 NBS 可以发现 C5DC 水平升高的新生儿 GA1 患者。由于婴儿的 C0 水平低,母体 GA1 患者也可以通过 NBS 检测到。由于在 NBS 中容易漏诊,少数新生儿 GA1 患者可能具有非典型的酰基肉碱谱,因此应在 C0 水平较低的新生儿中进行多基因panel 检测。本研究表明,在该中国南方队列中,GCDH 变异谱存在异质性。